Expressions and clinical significances of aldehyde dehydrogenase 1 and transforming growth factor-β2 in triple negative breast cancer

doi:10.3760/cma.j.issn.1673-422X.2017.11.001

Abstract

Abstract: Objective To investigate the expressions and clinical significances of breast cancer stem cell markers such as aldehyde dehydrogenase 1 (ALDH1) and transforming growth factorβ2 (TGFβ2) in patients with triple negative breast cancer. MethodsSamples of 60 triple negative breast cancer tissues were investigated for the expressions of ALDH1 and TGFβ2 proteins by immunohistochemical staining. The correlation analysis, diseasefree survival analysis and overall survival analysis were performed. ResultsThe positive expressions of ALDH1 protein and TGFβ2 protein in the 60 breast cancer primary lesions were 23 cases (38.33%) and 38 cases (63.33%) respectively. The expression of ALDH1 protein was not correlated with tumor size (χ2=0.307, P=0.580), histological grade (χ2=4.244, P=0.120), clinical stage (χ2=0.982, P=0.612) or lymph node metastasis (χ2=1.111, P=0.292). The expression of TGFβ2 protein was not correlated with histological grade (χ2=4.651, P=0.098), lymph node metastasis (χ2=3.513, P=0.061), clinical stage (χ2=1.310, P=0.519) or tumor size (χ2=0.629, P=0.428). The diseasefree survival time ［(38.43±3.86) months vs. (53.38±2.58) months］ and the overall survival time ［(42.00±3.11) months vs. (53.84±2.19) months］ of ALDH1positive patients were significantly shorter than those of ALDH1negative patients, and the differences were statistically significant (χ2=8.490, P=0.004; χ2=11.270, P=0.001). The diseasefree survival time ［(42.81±3.32) months vs. (54.72±2.50) months］ and the overall survival time ［(44.74±2.68) months vs. (57.18±1.55) months］ of TGFβ2 positive patients were significantly shorter than those of TGFβ2negative patients, and the differences were statistically significant (χ2=4.300, P=0.038; χ2=8.900, P=0.003). The expression of ALDH1 protein was positively correlated with the expression of TGFβ2 protein (r=0.360, P=0.005). ConclusionThe ALDH1 phenotype is an independent predictor of poor prognosis. The activation of TGFβ2 signaling pathway may be involved in the regulation of triplenegative breast cancer stem cells.

Key words: Breast neoplasms, Neoplastic stem cells, Transforming growth factor beta 2, Aldehyde dehydrogenase 1

Guo Chongyong, Li Yongmei, Li Bocheng, Zhou Ling, Zhang Jian, Jia Zongshi. Expressions and clinical significances of aldehyde dehydrogenase 1 and transforming growth factor-β2 in triple negative breast cancer[J]. Journal of International Oncology, 2017, 44(11): 801-805.

References

［1］ Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell［J］. Nat Med, 1997, 3(7): 730-737. ［2］ CharafeJauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer［J］. Clin Cancer Res, 2010, 16(1): 45-55. DOI: 10.1158/1078-0432.CCR-09-1630. ［3］ Ginestier C, Hur MH, CharafeJauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome［J］. Cell Stem Cell, 2007, 1(5): 555-567. DOI: 10.1016/j.stem.2007.08.014. ［4］ Mani SA, Guo W, Liao MJ, et al. The epithelialmesenchymal transition generates cells with properties of stem cells［J］. Cell, 2008, 133(4): 704-715. DOI: 10.1016/j.cell.2008.03.027. ［5］ Zubeldia IG, Bleau AM, Redrado M, et al. Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFβ1targeting peptides P17 and P144［J］. Exp Cell Res, 2013, 319(3): 1222. DOI: 10.1016/j.yexcr.2012.11.004. ［6］ Kim S, Han J, Jeon M, et al. Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-β2 expression［J］. Tumour Biol, 2016, 37(8): 11397-11407. DOI: 10.1007/s13277-016-5000-7. ［7］ Zhou L, Li K, Luo Y, et al. Novel prognostic markers for patients with triplenegative breast cancer［J］. Hum Pathol, 2013, 44(10): 2180-2187. DOI: 10.1016/j.humpath.2013.03.021. ［8］ Yu P, Zhou L, Wang JF, et al. Prognostic relevance of ALDH1 in breast cancer: a clinicopathological study of 96 cases［J］. ChineseGerman J Clin Oncol, 2010, 9(1): 31-35. DOI: 10.1007/s10330-009-0178-4. ［9］周凌, 虞佩, 王建丰, 等. 乙酰脱氢酶1蛋白在乳腺癌中的表达及临床意义［J］. 肿瘤, 2009, 29(7): 663-667. DOI: 10.3781/j.issn.1000-7431.2009.07.013. ［10］ Ma F, Li H, Li Y, et al. Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC)［J］. Medicine (Baltimore), 2017, 96(14): e6561. DOI: 10.1097/MD.0000000000006561. ［11］ Heldin CH, Landstrm M, Moustakas A. Mechanism of TGFbeta signaling to growth arrest, apoptosis, and epithelialmesenchymal transition［J］. Curr Opin Cell Biol, 2009, 21(2): 166-176. DOI: 10.1016/j.ceb.2009.01.021. ［12］ Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression［J］. Nat Rev Cancer, 2010, 10(6): 415-424. DOI: 10.1038/nrc2853. ［13］ Yang L, Pang Y, Moses HL. TGFbeta and immune cells: an important regulatory axis in the tumor microenvironment and progression［J］. Trends Immunol, 2010, 31(6): 220-227. DOI: 10.1016/j.it.2010.04.002. ［14］ Yang HP, Schneider SS, Chisholm CM, et al. Association of TGFβ2 levels in breast milk with severity of breast biopsy diagnosis［J］. Cancer Causes Control, 2015, 26(3): 345-354. DOI: 10.1007/s1055201404988. ［15］ MuraokaCook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression［J］. Clin Cancer Res, 2005, 11(2 Pt 2): 937s943s. ［16］ Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer［J］. Nat Rev Cancer, 2006, 6(7): 506-520. DOI: 10.1038/nrc1926. ［17］ Bueno L, de Alwis DP, Pitou C, et al. Semimechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type Ⅰ receptor TGFbeta kinase antagonist, in mice［J］. Eur J Cancer, 2008, 44(1): 142-150. DOI: 10.1016/j.ejca.2007.10.008. ［18］ Kim S, Lee J, Jeon M, et al. Elevated TGF-β1 and β2 expression accelerates the epithelial to mesenchymal transition in triplenegative breast cancer cells［J］. Cytokine, 2015, 75(1): 151-158. DOI: 10.1016/j.cyto.2015.05.020. ［19］ Bhola NE, Balko JM, Dugger TC, et al. TGF-β inhibition enhances chemotherapy action against triplenegative breast cancer［J］. J Clin Invest, 2013, 123(3): 1348-1358. DOI: 10.1172/JCI65416. ［20］郭崇勇, 李克, 周凌, 等. 长程多柔比星化疗富集乳腺肿瘤干细胞［J］. 肿瘤, 2012, 32(1): 27-31. DOI: 10.3781/j.issn.1000-7431.2012.01.005. ［21］ Hoshino Y, Nishida J, Katsuno Y, et al. Smad4 decreases the population of pancreatic cancerinitiating cells through transcriptional repression of ALDH1A1［J］. Am J Pathol, 2015, 185(5): 1457-1470. DOI: 10.1016/j.ajpath.2015.01.011.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng. Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors [J]. Journal of International Oncology, 2023, 50(11): 650-654.